Orchestra BioMed Holdings, Inc. OBIO
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -89.43% | -89.47% | -87.33% | 12,120.16% | -12.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -89.43% | -89.47% | -87.33% | 12,120.16% | -12.77% |
| Cost of Revenue | -42.86% | -45.65% | -27.27% | -12.07% | -27.94% |
| Gross Profit | -92.24% | -92.03% | -90.53% | 15,728.72% | -11.64% |
| SG&A Expenses | -20.75% | -6.94% | 1.76% | 23.52% | 25.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.45% | 11.31% | 12.11% | 42.72% | 22.19% |
| Operating Income | -14.69% | -15.67% | -16.67% | 140.50% | -24.30% |
| Income Before Tax | 9.98% | -22.68% | -10.32% | 138.66% | -35.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.98% | -22.68% | -10.32% | 138.66% | -35.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.98% | -22.68% | -10.32% | 138.66% | -35.02% |
| EBIT | -14.69% | -15.67% | -16.67% | 140.50% | -24.30% |
| EBITDA | -14.65% | -15.66% | -16.71% | 141.20% | -24.38% |
| EPS Basic | 23.93% | 25.18% | 32.74% | 122.79% | 2.66% |
| Normalized Basic EPS | 3.45% | 26.05% | 25.47% | 123.75% | 2.69% |
| EPS Diluted | 23.93% | 25.18% | 32.74% | 122.79% | 2.66% |
| Normalized Diluted EPS | 3.45% | 26.05% | 25.47% | 123.75% | 2.69% |
| Average Basic Shares Outstanding | 23.83% | 66.21% | 64.04% | 62.80% | 38.71% |
| Average Diluted Shares Outstanding | 23.83% | 66.21% | 64.04% | 62.80% | 38.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |